India, Aug. 5 -- Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, said on Wednesday that Health Canada approved its cancer drug Keytruda in combination with enfortumab vedotin for certain adults with muscle-invasive bladder cancer.
The approval covers patients who are ineligible for cisplatin-containing chemotherapy. Keytruda will be used as neoadjuvant treatment, followed by radical cystectomy, and then continued as adjuvant treatment after surgery.
Keytruda, or pembrolizumab, is Merck's anti-PD-1 therapy. Enfortumab vedotin is an antibody-drug conjugate. The approval was based on data from the Phase 3 KEYNOTE-905 trial, also known as EV-303.
The trial was conducted with Pfizer Inc. (PFE) and Astellas Pharma I...